What is the most likely outcome of erythropoietin therapy in a woman with early-stage chronic kidney disease and anemia?

In the context of erythropoietin therapy for a woman with early-stage chronic kidney disease and anemia, the most likely outcome is an improvement in exercise tolerance. Erythropoietin, a hormone produced by the kidneys, stimulates the production of red blood cells (RBCs) in the bone marrow. In patients with anemia, particularly in those with chronic kidney disease, erythropoietin therapy can lead to an increase in hemoglobin levels.

As hemoglobin levels rise, the oxygen-carrying capacity of the blood improves, which enhances the overall oxygenation of tissues and organs. This translates to improved physical performance and exercise capacity, allowing the patient to engage in daily activities with less fatigue and greater endurance.

While increased ventricular hypertrophy could be a consequence of untreated anemia due to prolonged hypoxia and increased cardiac workload, it is not typically a direct and immediate outcome of erythropoietin therapy. Instead, the therapy primarily targets the anemia itself, which is closely linked to improved exercise tolerance.

The other outcomes provided in the choices relate to different aspects of health that may not be directly affected by erythropoietin therapy in this specific context. Improved blood pressure control is not a direct result of correcting